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Background: Acute myeloid leukemia (AML) is a heterogeneous neoplasm of the bone marrow with poor prognosis.
In clinical practice new prognostic factors are still needed. MicroRNAs (miRs), small endogenous noncoding RNAs, play
an essential role in the development and progression of acute leukemia. The aim of the study was to evaluate miR-204
expression in patients with AML at diagnosis and after induction chemotherapy, in comparison to healthy controls. We
also investigated, if miR-204 expression correlates with clinical features of AML patients.
Methods: miR-204 expression has been analyzed using RT-PCR in 95 bone marrow specimens from newly diagnosed
AML patients in comparison to 20 healthy subject.
Results: We showed down-regulated miR-204 expression in AML patients, which was associated with shorter patients’
survival. Higher expression of miR-204 in patients after induction therapy was correlated with complete remission
achieving.
Conclusions: We showed low miR-204 expression in AML and found it to be an independent prognostic factor in this
patient population.
Keywords: miR-204, Acute myeloid leukemia, Expression, Survival, PrognosisIntroduction
Acute myeloid leukemia (AML) in adults is a hematological
malignancy with proliferation of myeloblasts in the bone
marrow. Population of AML patients has heterogenous
clinical course and different prognosis. Although dynamic
progress on the field of pathogenesis and development of
this blood cancer has been made, it is still difficult to
predict clinical outcome and response to therapy of AML
patients. Genetic and molecular markers are used in every
day practice, but new predictors are needed, for better
patients’ classification and therapy planning [1, 2].
microRNA (miRs) are small non-coding RNAs,
which play an important role in neoplastic trans-
formation. miRs act by influencing posttranscriptional* Correspondence: aleksandra.butrym@gmail.com
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ation and apoptosis [3–8].
microRNA-204 (miR-204) role has been investigated
and described in few solid tumors, particularly pancre-
atic and colorectal cancer, where it was found to be
associated with process of autophagy [3, 9]. But there is
no data about miR-204 role in acute myeloid leukemia.
The purpose of this study was to evaluate miR-204 ex-
pression in AML patients in relation to clinical factors,
survival and comparison to healthy subjects.Material and methods
Patients characteristic
The study included 95 patients (aged 60.2 ± 15.0, 22–90,
Male = 61 %) with newly diagnosed AML. Samples of
the bone marrow for miR-204 expression analysis were
collected before start of chemotherapy and repeated
after completed induction chemotherapy (in 40 patients).
Patients were treated in the Department of Hematology,rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Lactate dehydrogenase (LDH) U/l
Range 108-4565
Median 340










Best supportive care 12







Yes (after 1st line therapy) 36
No 44
Duration of remission (months)
Range 2-54
Median 20
Table 1 Clinical characteristics of patients with AML (Continued)
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Wroclaw Medical University, Wroclaw, Poland. A con-
trol group of 20 healthy subjects was also taken into ac-
count (aged 64.2 ± 10.5, 39–80, Male = 65 %). According
to AML FAB classification, 7 patients had AML M0, 34
had M1, 29 had M2, 14 had M4 and 11 had M5. There
were 73 patients with primary leukemia and 22 patients
with leukemia secondary to myelodysplastic or myelo-
proliferative syndrome. Summary of patients’ character-
istics is presented in Table 1.
Treatment schedules
Fifty six patients were treated with standard induction
intensive chemotherapy (daunorubicin plus cytarabine
3 + 7), 27 received low dose chemotherapy (low dose
cytarabine or azacitidine) and 12 best supportive care
only. After completion of induction therapy response
to treatment was evaluated. CR was defined by Cheson cri-
teria. [10]. 40 bone marrow samples were re-evaluated for
miR-204 expression after chemotherapy. Patients were
followed up for median 21 month (range 1–40 months).
Research was carried out in compliance with the
Helsinki Declaration. For the study approval of Bioethical
Committee of Wroclaw Medical University was obtained.
Written informed consent for study was obtained from all
the participants.
Isolation and expression analysis of microRNAs
Bone marrow mononuclear cells (PBMC) were isolated
by Ficoll-Hypaque density gradient centrifugation. Total
RNA and microRNA were extracted from collected
AML mononuclear cells using mirVana™ miRNA Iso-
lation Kit (Ambion) according to the protocol of the
manufacturer. Then 5 μl total miRNA was used as a tem-
plate into synthesis of cDNA using TaqMan MicroRNA
Trasncription Reaction Kit (Applied Biosystems) and 3 μl
specific miRNA primers from the TaqMan MicroRNA
Assays (Applied Biosystems). Individual reaction was car-
ried out in 15 μl total volume in thermal condition: 16 °C
for 30 min, 42° for 30 min, 85 °C for 5 min. TaqMan
MicroRNA Assays for miR-204 (hsa-miR-204), and
RNU48 were used. The expression level of each micro-
RNA was measured in relative real-time PCR method
using TaqMan Gene Expression Assays and TaqMan Fast
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tions were done in triplicate in a total volume of 20 μl on
96-well plates. The real-time PCR was performed on
7900HT Fast Real-Time PCR System (Applied Biosys-
tems) under thermal cycling conditions: 20 s at 95 °C and
40 cycles of 1 s at 95 °C and 20 s at 60 °C. For quantifica-
tion, the samples were normalized against the expression
of RNU48 (internal control). Relative quantification fac-
tors (RQ) for the examined miRs were calculated using
ΔΔCT method.
Statistical analysis
The differences in means of gene expressions between the
study and the control patients were estimated using t-
Student’s test (for independent samples). To examine the
time it takes for death and remission to occur, a Cox’s re-
gression was applied [11]. The difference between the
gene expressions before and after treatment was estimated
using robust regression and multivariate approach [12].
The computation was performed in R software [13] and
based on the simulation technique known as Gibbs sam-
pling in WinBUGS platform [14]. Kaplan-Meier survival
curves were used to determine any significant relationship
between miR-204 expression and clinical outcome. Results
were considered statistically significant when p was <0.05.
Results
We compared AML samples to healthy controls and
found significantly lower miR-204 expression in AML
patients (p < 0.05). There were no differences in miR-204
expression between male and female patients.Fig. 1 Correlation between miR-204 expression after chemotherapy
and remissionAfter successful induction chemotherapy expression
of miR-204 significantly increased (median 0.443606;
p = 0.000590). Patients with increased miR-204 ex-
pression after induction therapy had higher chance
for remission (p = 0.01438). 83 % of pts with CR after
induction therapy had high miR-204 expression and
60 % of patients who did not respond to therapy had
low miR-204 expression (Fig. 1). At the moment of
diagnosis, Mean miR-204 expression in group who
achieved CR was significantly lower than in the group
which did not achieve response.
In patients with increase of miR-204 expression
after chemotherapy time to relapse was longer (median
13 months) than in patients with decreased miR-204 ex-
pression (median 4.5 months), p = 0.003347, Fig. 2.
miR-204 expression level also influenced patients’
outcome (median value was used as a cut-off ). Higher
miR-204 expression before therapy was associated with
longer survival (Fig. 3).
Discussion
Small non-coding microRNAs affect process of forma-
tion, development, proliferation and apoptosis of normal
and malignant cells in human body. Their role has been
proved in many cancers, including leukemia [4, 15–17].
Pathways regulation based on microRNA expression is
still unknown. Some miRs may act as tumor suppressors
and others as oncogenes [18, 19]. Recently, many miRs
have been investigated as prognostic and predictive
markers. miR-204 expression and its role has been
studied in some solid tumors: pancreatic, gastric, prostate
[3, 9, 20], in which it acts by down-regulation of Bcl-2 and
has tumor suppressor role. miR-204 also influences
NTRK2 gene expression in neuroblastoma cancer [21] and
FOXC1 gene in invasive endometrial cancer [22].
In our study we showed down-regulated expression of
miR-204 in acute myeloid leukemia patients comparingFig. 2 miR-204 expression after chemotherapy and time to relapse
Fig. 3 Predicted overall survival depending on miR-204 expression before chemotherapy
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made by Garzon et al. [23]. Authors found lower
miR-204 expression in nucleophosmin positive AML
patients and assumed hypothesis, that miR-204 targeted
HOXA10 and MEIS1. Those two genes perturb myeloid
differentiation and can lead to AML. Ying et al. in their
study revealed that loss of miR-204 promotes cancer cell
migration through increased expression of brain derived
neurotrophic factor or its TrkB receptor [24]. In gastric
cancer loss of miR-204 expression was associated with
poor outcome, because it caused increase of antiapopto-
tic protein Bcl-2. In the light of these results Chen et al.
demonstrated that miR-204 was down-regulated and its
overexpression leaded to loss of cancer cell viability in
pancreatic cancer [3]. Authors also showed that miR-204
regulates expression of Mcl-1 (Myeloid cell leukemia) by
direct binding to 3′UTR [3]. Overexpressed Mcl-1 is as-
sociated with cell survival, while its downregulation leads
to cell death. Increased miR-204 negatively regulated
Mcl-1. Those observations could explain results of our
study. We also analyzed correlations between miR-204 at
diagnosis and after chemotherapy and clinical outcome.
After effective induction chemotherapy we observed in-
creased miR-204 expression and this change correlatedpositively with chance for remission achieving. Sup-
posedly higher miR-204 expression could induce
leukemic cell deaths and leaded to disease remission. On
the other side, patients who had higher miR-204 expres-
sion at diagnosis had more favorable clinical outcome
than others. Similar role of miR-204 has been also proved
in gliomas, where low miR-204 expression leaded to a
stem cell-like phenotype, and its overexpression resulted
in reduced tumorigenicity and loss of stemness transcrip-
tion factor SOX4 [24]. In contrast were results by
Sümbül et al., who detected high miR-204 expression in
colorectal cancer in comparison to healthy population.
This finding was not related to any clinicopathological
parameters nor survival [9]. Authors explained discrepant
findings by the role of increased miR-204 in autophagy
and apoptosis.
Concluding, as to our knowledge, we found for the
first time down-regulated miR-204 expression in acute
myeloid leukemia patients with its implication to disease
prognosis. Functionality of miR-204 acting as a tumor
suppressor makes this new molecule an useful bio-
marker in cancer diagnosis and management. Further
investigation on miR-204 regulation and its target genes
should be performed.
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